hATTR Amyloidosis


Webinar: “Progress in Amyloidosis: 2022”

Webinar: “Progress in Amyloidosis: 2022”

July 2022 Webinar Event

View the recorded webinar below

View Webinar Here

Dr. Zonder will describe recent advances in the management of AL amyloidosis; review approved therapies for ATTR amyloidosis and how they work, and discuss new classes of agents designed to help remove existing amyloid deposits.

Jeffrey Zonder, MD, is a Professor in the Departments of Oncology at the Barbara Ann Karmanos Cancer Institute (KCI) and Wayne State University School of Medicine. He is the Leader of the KCI Multiple Myeloma and Amyloidosis Multidisciplinary Team and Co-Leader of the Molecular Therapeutics Program. He is a member of the Steering Committee of the Multiple Myeloma Research Consortium and a medical advisor for the Amyloidosis Support Groups Networks. Dr. Zonder is a member of the International Myeloma Working Group, the International Myeloma Society, and the International Society of Amyloidosis.  He is a member of the Southwest Oncology Group’s (SWOG) Barlogie-Salmon Myeloma Committee. Dr. Zonder has authored or co-authored numerous original research papers, review articles, book chapters, and research abstracts on myeloma and amyloidosis.

He completed a fellowship in hematology-oncology at Wayne State University and his medical residency at the University of Rochester, New York.  He received his medical degree from Wayne State University School of Medicine.

Sponsored by:


Webinar: “Progress in Amyloidosis: 2022”

Webinar: “Progress in Amyloidosis: 2022”

July 2022 Live Webinar Event

Please join us for our webinar event presented by Dr. Jeffrey Zonder

on

July 13, 2022, at 2:30 pm ET

Register Here

Dr. Zonder will describe recent advances in the management of AL amyloidosis; review approved therapies for ATTR amyloidosis and how they work, and discuss new classes of agents designed to help remove existing amyloid deposits.

Jeffrey Zonder, MD, is a Professor in the Departments of Oncology at the Barbara Ann Karmanos Cancer Institute (KCI) and Wayne State University School of Medicine. He is the Leader of the KCI Multiple Myeloma and Amyloidosis Multidisciplinary Team and Co-Leader of the Molecular Therapeutics Program. He is a member of the Steering Committee of the Multiple Myeloma Research Consortium and a medical advisor for the Amyloidosis Support Groups Networks. Dr. Zonder is a member of the International Myeloma Working Group, the International Myeloma Society, and the International Society of Amyloidosis.  He is a member of the Southwest Oncology Group’s (SWOG) Barlogie-Salmon Myeloma Committee. Dr. Zonder has authored or co-authored numerous original research papers, review articles, book chapters, and research abstracts on myeloma and amyloidosis.

He completed a fellowship in hematology-oncology at Wayne State University and his medical residency at the University of Rochester, New York.  He received his medical degree from Wayne State University School of Medicine.

Sponsored by:


Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

Jun 13, 2022

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 13, 2022– Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) approved AMVUTTRA™ (vutrisiran), an RNAi therapeutic administered via subcutaneous injection once every three months (quarterly) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. hATTR amyloidosis is a rare, inherited, rapidly progressive, and fatal disease with debilitating polyneuropathy manifestations, for which there are few treatment options. The FDA approval is based on positive 9-month results from the HELIOS-A Phase 3 study, where AMVUTTRA significantly improved the signs and symptoms of polyneuropathy, with more than 50 percent of patients experiencing halting or reversal of their disease manifestations.

View the full release here: https://www.businesswire.com/news/home/20220603005487/en/


Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy

Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 27, 2021– Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of the polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis, met all secondary endpoints measured at 18 months

Read the full press release here.